Comparison of the cytotoxic effect of Embelin with tamoxifen and docetaxel on human breast cancer MCF-7 and MDA MB-231 cell proliferation

pathways, preparations stained with proapoptotic Bax and antiapoptotic Bcl-2 were examined. Accordingly, while Bax expression level increased (p<0.05), Bcl-2 expression level decreased (p<0.05). Conclusion: In general, Embelin inhibits cancer cell proliferation in both breast cancer cell types, depending on dose and time. We found that Embelin was statistically more effective at the molecular level when compared to both Tamoxifen and Docetaxel, especially in hormone receptor-negative MDA MB-231 cells. By concluding that it is more effective especially in hormone receptor-negative breast cancer, Embelin may be an alternative new antitumoral agent in the treatment of breast cancer in the future. The results of this study may guide for in vivo studies in future.